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benefits in single HCC. A total of 470 patients with a diagnosis of single HCC between 2005
and 2010 were studied. The factors associated with clinical outcomes were analyzed. The out-
comes between patients who underwent neoadjuvant TACE and those who did not were also
compared. The 1-, 3-, and 5-year overall survival (OS) rates of all patients were 92.6%,
73.3%, and 59.6%, respectively. Child-Pugh class A [HR: 2.04, 95% confidence interval (CI):
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78 M.-L. Yeh et al.pZ 0.001), and curative-based therapy (HR: 2.16, 95% CI: 1.442e3.224, p < 0.001) were fac-
tors associated with better OS. The 1-, 3-, and 5-year disease-free survival (DFS) rates of all the
patients were 75.4%, 53.7%, and 36.3%, respectively. Only Child-Pugh class A (HR: 1.57, 95% CI:
1.068e2.294, p Z 0.022) and curative-based therapy (HR: 1.51, 95% CI: 1.128e2.028,
p Z 0.006) were significantly associated with better DFS. Neoadjuvant TACE did not provide
benefit compared with curative therapy alone in subgroup analysis. In conclusion, neoadjuvant
TACE is not recommended in single HCC patients who may indicate for curative therapy.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the third leading cause of cancer death world-
wide [1,2]. For single nodular type HCC, curative therapies,
including hepatic resection (HR), radiofrequency ablation
(RFA), and percutaneous ethanol injection (PEI), are the
recommended treatments [3]. However, HR is not always
recommended in larger HCC owing to reserve function and
RFA/PEI is not primarily recommended in HCC > 5 centi-
meters (cm); transcatheter arterial chemoembolization
(TACE) is the main palliative treatment for these HCCs [4].
TACE shows a significant beneficial effect for intermediate
or advanced stage HCC, but not for early stage HCC [5].
However, in early stage HCC patients who are not suitable
for or not selected for curative therapy, TACE is a safe and
effective option with a favorable long-term outcome [6].
TACE can reduce tumor arterial blood flow, causing
ischemic necrosis, and is expected to potentially enhance
the effects of sequential RFA or HR. The use of TACE as a
neoadjuvant therapy for HCC was first described in the
1990s. The purpose of TACE prior to surgery or local abla-
tion therapy is to reduce the tumor size and to avoid
further tumor cell dissemination. A previous meta-analysis
demonstrated an improved 2-year survival with TACE in
unresectable HCC [7]. It has also been reported that TACE
performed prior to HR significantly reduced the incidence
of HCC recurrence and related death [8]. Moreover, a
recent study by Kagawa et al [9] reported that RFA com-
bined with TACE did not have a beneficial effect over sur-
gical resection alone.
It remains unclear whether using TACE as a neoadjuvant
therapy for HCC is effective in reducing postcurative ther-
apy recurrence and prolonging survival. In this study, our
aim was to elucidate the survival of single HCC in Taiwan
and also to clarify whether TACE plus sequential curative
therapy has superior effects than curative therapy alone in
single HCC patients.
Methods
Patients
This cohort study was conducted as a retrospective analysis
of a cancer registration database in our hospital, Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan. Patients
who were registered as HCC in our cancer registration
database from January 2005 to January 2010 wereconsidered eligible for this study. The diagnosis of HCC was
made by at least two radiologic imaging assessments
showing the typical features of HCC (early enhancement in
the arterial phase and early wash-out in the delay venous
phase), one radiologic imaging assessment showing the
typical features of HCC associated with a serum alpha
fetoprotein (AFP) level  400 ng/mL, or cytologic/histo-
logic evidence. The diagnostic criteria for HCC of the
Kaohsiung Medical University Hospital were modified from
regional guidelines and each patient who was diagnosed as
HCC had their diagnosis confirmed by the HCC expert group.
All enrolled patients met the following inclusion criteria:
(1) HCC of tumor stage 1 (the American Joint Committee on
Cancer TNM Classification, stage 1dsingle liver tumor,
neither lymph node nor distant metastasis); (2) Child-Pugh
classification A or B; (3) Barcelona Clinic Liver Cancer
(BCLC) staging classification very early stage (stage 0) or
early stage (stage A) HCC. Patients with Child-Pugh class C
liver function were excluded because their treatment op-
tion was limited to liver transplantation.
From the cancer registration database, the patient’s
basic and follow-up data, including sex, age, etiology of
HCC, Child-Pugh class, BCLC stage, serum AFP level, tumor
size, tumor response, recurrence status, and survival
period were obtained for further analysis. The endpoints of
the study included overall survival (OS) and disease-free
survival (DFS) and whether TACE plus sequential curative
therapy provided any benefit compared to curative therapy
alone.
This study only analyzed aggregated secondary data,
without identifying specific patients, and the study proto-
col conformed to the ethical standards established by the
1964 Declaration of Helsinki, which waives the requirement
for written or verbal patient consent in data linkage
studies. The study was approved by the Ethic Committee of
Kaohsiung Medical University Hospital (KMUH-IRB-EXEMPT-
20140018).Definitions
OS refers to the period after the first treatment until death
or loss of follow-up. DFS refers to the period after the first
treatment until the occurrence of any one of the following:
recurrence (local, regional, or distant), death, or loss of
follow-up. TACE plus sequential curative therapy was
defined as curative therapy including HR, RFA, or PEI per-
formed within 2 months after TACE.
Table 1 Baseline characteristics of all patients and each group of patients.
All Curative therapy
alone
TACE plus curative
therapy
TACE alone p
Number 470 190 (40.4) 70 (14.9) 210 (44.7)
Male sex 312 (66.4) 121 (63.7) 54 (77.1) 137 (65.2) 0.773
Age, y 63.0 (54.0, 71.0) 59.0 (52.0, 68.0) 60.5 (51.0, 67.3) 67.0 (57.0, 74.0) < 0.001
Follow-up period, mo 26.6 (16.8, 42.1) 30.1 (17.6, 44.8) 27.4 (18.6, 42.6) 24.1 (15.0, 39.0) 0.034
HBVa 182 (39.6) 70 (38.0) 32 (45.7) 80 (38.8) 0.822
Child-Pugh classification Ab 396 (85.9) 162 (86.6) 61 (89.7) 173 (84.0) 0.441
BCLC stage 0c 91 (20.6) 51 (27.3) 13 (20.3) 27 (14.1) 0.002
Tumor size, cm 2.7 (2.0, 4.0) 2.5 (1.8, 3.2) 2.5 (2.0, 4.0) 3.0 (2.2, 5.0) < 0.001
Tumor size < 5 cmd 370 (82.4) 173 (91.1) 53 (81.5) 144 (74.2) < 0.001
AFP level, ng/mL 15.4 (6.2, 98.3) 15.4 (6.0, 95.3) 11.8 (6.0, 80.7) 17.3 (6.2, 132.6) 0.597
AFP < 200e 346 (80.5) 138 (80.2) 51 (82.3) 157 (80.1) 0.967
Continuous variable: median (25th percentile, 75th percentile), statistics with KruskaleWallis one-way test.
Categorical variable: n (%), statistics with Chi-square test.
AFP Z alpha fetoprotein; BCLC Z Barcelona Clinic Liver Cancer; HBV Z hepatitis B virus; TACE Z transcatheter arterial
chemoembolization.
a Missing data in 10 of all patients (6 in curative therapy alone group and 4 in TACE alone group).
b Missing data in nine of all patients (3 in curative therapy alone group, 2 in TACE plus curative therapy group, and 4 in TACE alone
group).
c Missing data in 28 of all patients (3 in curative therapy alone group, 6 in TACE plus curative therapy group, and 19 in TACE alone
group).
d Missing data in 21 of all patients (5 in TACE plus curative therapy group and 16 in TACE alone group).
e Missing data in 40 of all patients (18 in curative therapy alone group, 8 in TACE plus curative therapy group, and 14 in TACE alone
group).
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The medians, 25th percentile, and 75th percentile were used
to describe the distribution of continuous variables.
Numbers and percentages were used to describe the distri-
bution of categorical variables. OS and DFS were analyzed by
the KaplaneMeier actuarial curve method with the log-rank
test. The Cox regression hazard model was used to identify
the independent predictive factors for OS and DFS. All tests
were two-sided, and a p < 0.05 was considered statistically
significant. All analyses were performed using the SPSS 17.0
statistical package (SPSS Inc., Chicago, IL, USA).Results
In total, 470 patients with single nodular type HCC were
enrolled into the study. Table 1 showed the demographicsTable 2 Factors associated with OS.
Parameter KaplaneMeier an
p
Male vs. female 0.090
Age <60 y vs.  60 y 0.032
HBV vs. HCV vs. others 0.914
Child-Pugh A vs. B < 0.001
BCLC stage 0 vs. A 0.001
Tumor size < 5 cm vs.  5 cm < 0.001
AFP level < 200 ng/mL vs.  200 ng/mL < 0.001
Curative-based therapy vs. TACE alone < 0.001
AFPZ alpha fetoprotein; BCLCZ Barcelona Clinic Liver Cancer; CIZ
virus; OS Z overall survival; TACE Z transcatheter arterial chemoemof all and each group of patients. Of them, 312 (66.4%)
patients were male and the median age was 63 years old.
The median follow-up period was 26.6 months. Approxi-
mately 40% of patients had hepatitis B virus (HBV) infec-
tion. In most of the patients (85.9%), liver function was
compensated. The BCLC tumor stages were very early stage
in 20.6% of patients. The median tumor size was 2.7 cm and
the tumor size was <5 cm in 82.4% of patients. The median
serum AFP level was 15.4 ng/mL and most of the patients
had an AFP level <200 ng/mL. In total, 190 (40.4%) patients
received curative therapy, including HR in 125 patients, RFA
in 47 patients, and PEI in 18 patients. There was no sig-
nificant difference in baseline characteristics and survival
between HR and RFA/PEI (data not shown). The others
received TACE alone (44.7%) or TACE plus sequential cura-
tive therapy (14.9%). Comparing the baseline characteris-
tics between the three treatment groups, there had
significant differences in age, follow-up period, BCLC stage,alysis Cox regression hazard analysis
HR 95% CI p
1.28 0.851e1.929 0.236
2.04 1.277e3.254 0.003
2.03 1.021e4.025 0.043
1.75 1.115e2.751 0.015
2.07 1.346e3.182 0.001
2.16 1.442e3.224 < 0.001
confidence interval; HBVZ hepatitis B virus; HCVZ hepatitis C
bolization.
Figure 1. Overall survival (OS) according to treatment.
Curative therapy alone and transcatheter arterial chemo-
embolization (TACE) plus sequential curative therapy had
better OS compared to therapy with TACE alone (p < 0.001,
pZ 0.047). There was no significant difference in OS between
curative therapy alone and TACE plus sequential curative
therapy (p Z 0.059). Pts at risk Z the number of patients
without death or loss of follow-up at each time point.
80 M.-L. Yeh et al.and tumor size. Patients receiving TACE therapy alone had
significantly younger age, shorter follow-up period, less
BCLC very early stage, and larger tumor size. There was a
significant difference in tumor size (< 5 cm) between
curative therapy alone (91.1%) and TACE plus curative
therapy group (81.5%; p Z 0.044). The other baseline pa-
rameters did not show differences between the two groups.Factors associated with OS
The 1-, 3-, and 5-year OS rates of all the patients were
92.6%, 73.3%, and 59.6%, respectively. The factors associ-
ated with OS were further analyzed. KaplaneMeier analysis
showed that age < 60 years (pZ 0.032), Child-Pugh class A
(p < 0.001), BCLC very early stage (p Z 0.001), tumor
size < 5 cm (p < 0.001), AFP level < 200 ng/mL (p < 0.001),Table 3 Factors associated with DFS.
Parameter KaplaneMeier a
p
Male vs. female 0.054
Age < 60 y vs.  60 y 0.098
HBV vs. HCV vs. others 0.657
Child-Pugh A vs. B 0.002
BCLC stage 0 vs. A 0.016
Tumor size < 5 cm vs.  5 cm 0.021
AFP level < 200 ng/mL vs.  200 ng/mL 0.057
Curative-based therapy vs. TACE alone < 0.001
AFPZ alpha fetoprotein; BCLCZ Barcelona Clinic Liver Cancer; CIZ
B virus; HCV Z hepatitis C virus; TACE Z transcatheter arterial chemand curative-based therapy (p < 0.001) were factors that
were significantly associated with better OS. Cox regression
hazard analysis revealed Child-Pugh class A [HR: 2.04, 95%
confidence interval (CI): 1.277e3.254, p Z 0.003], BCLC
very early stage (HR: 2.03, 95% CI: 1.021e4.025,
p Z 0.043), tumor size < 5 cm (HR: 1.75, 95% CI:
1.115e2.751, pZ 0.015), AFP level < 200 ng/mL (HR: 2.07,
95% CI: 1.346e3.182, p Z 0.001), and curative-based
therapy (HR: 2.16, 95% CI: 1.442e3.224, p < 0.001) as in-
dependent factors (Table 2). Curative alone therapy and
TACE plus sequential curative therapy had better OS
compared to therapy with TACE alone (p < 0.001 and
p Z 0.047, respectively). Additionally, there was no sig-
nificant difference in OS between curative alone therapy
and TACE plus sequential curative therapy (p Z 0.059;
Fig. 1).
Factors associated with DFS
The 1-, 3-y, and 5-year DFS rates of all the patients were
75.4%, 53.7%, and 36.3%, respectively. KaplaneMeier
analysis showed that Child-Pugh class A (p Z 0.002), very
early stage BCLC (p Z 0.016), tumor size < 5 cm
(pZ 0.021), and curative-based therapy (p < 0.001) were
factors that were significantly associated with better DFS.
Cox regression hazard analysis revealed Child-Pugh class A
(HR: 1.57, 95% CI: 1.068e2.294, p Z 0.022) and curative-
based therapy (HR: 1.51, 95% CI: 1.128e2.028, pZ 0.006)
as independent factors (Table 3). Curative therapy alone
resulted in better DFS compared to TACE therapy alone
(p < 0.001). Additionally, there was no significant differ-
ence in DFS between curative therapy alone and TACE plus
sequential curative therapy (p Z 0.141), TACE plus
sequential curative therapy, and TACE therapy alone
(p Z 0.134) (Fig. 2).
OS and DFS with curative therapy alone and TACE
plus sequential curative therapy
We further analyzed whether TACE plus sequential curative
therapy provided benefits compared to curative therapy
alone, according to different parameters. We found that
TACE plus sequential curative therapy did not providenalysis Cox regression hazard analysis
HR 95% CI p
1.18 0.869e1.595 0.291
1.57 1.068e2.294 0.022
1.36 0.887e2.078 0.159
1.16 0.801e1.691 0.425
1.30 0.911e1.844 0.150
1.51 1.128e2.028 0.006
confidence interval; DFSZ disease-free survival; HBVZ hepatitis
oembolization.
Figure 2. Disease-free survival (DFS) according to treat-
ment. Curative therapy alone resulted in better DFS compared
to transcatheter arterial chemoembolization (TACE) therapy
alone (p < 0.001). There was no significant difference in DFS
between curative therapy alone and TACE plus sequential
curative therapy (pZ 0.141) and TACE plus sequential curative
therapy and TACE therapy alone (pZ 0.134). Pts at riskZ the
numbers of patient without recurrence, death, or loss of
follow-up at each time point.
Neoadjuvant TACE for single HCC 81benefits in OS and DFS according to various parameters,
including sex, age, etiology, Child-Pugh class, BCLC stage,
tumor size, or AFP level. By contrast, TACE plus sequential
curative therapy resulted in significantly lower OS in pa-
tients of Child-Pugh class A (pZ 0.015) and BCLC very early
stage (p Z 0.002) and lower DFS in patients of BCLC very
early stage (p Z 0.004) (Table 4).Table 4 Comparison of OS and DFS between curative therapy a
different parameters.a
Parameter Patient no.
All (TACE plus/
curative alone)
Media
TA
cura
Male 175 (54/121) 29
Female 85 (16/69) 23
Age < 65 y 162 (42/120) 29
 65 y 98 (28/70) 26
Etiology HBV 102 (32/70) 29
HCV 99 (23/76) 25
Others 53 (15/38) 28
CTP class A 223 (61/162) 29
B 32 (7/25) 28
BCLC stage 0 64 (13/51) 22
 A 187 (51/136) 29
Tumor size < 5 cm 226 (53/173) 29
 5 cm 29 (12/17) 22
AFP level < 200 ng/mL 189 (51/138) 29
 200 ng/mL 45 (11/34) 20
AFPZ alpha fetoprotein; BCLCZ Barcelona Clinic Liver Cancer; DFSZ
C virus; OS Z overall survival; TACE Z transcatheter arterial chemoe
a Statistical analysis with KaplaneMeier.Discussion
In the present study of patients with single HCC, the 5-year
OS and DFS rates were 59.6% and 36.3%, respectively. The
positive predictors for OS included Child-Pugh class A, BCLC
very early stage, tumor size < 5 cm, AFP level < 200 ng/mL,
and curative-based therapy. Child-Pugh class A and
curative-based therapy were associated with better DFS.
The results also demonstrated that there was no difference
in OS and DFS between patients who underwent TACE plus
sequential curative therapy and those who underwent
curative therapy alone. On the contrary, significantly worse
OS and DFS was found in patients of Child-Pugh class A and
very early stage BCLC receiving TACE plus sequential
curative therapy.
A recent systemic review article by Chua et al [10]
focused on neoadjuvant TACE for resectable HCC. Four of
the 18 studies in the review article reported an improve-
ment in DFS [8,11e13] and 12 of the 18 studies (67%) re-
ported no difference [10]. Notably, six of the 12 studies
reporting no significant difference in DFS further demon-
strated a poor median DFS in the TACE group [12,14e16].
For OS, only one study in the review article reported a
longer median OS and 5-year survival in the TACE group
compared to the non-TACE group [11]. Because of the
heterogeneous results, the authors concluded that the ef-
fect of neoadjuvant TACE in OS was inconclusive.
Lee et al [17] also conducted a similar study and found
that the liver resection group had a significantly higher OS
(52.5% vs. 47.1%, p Z 0.025), but no significant difference
in DFS (p Z 0.955). Preoperative TACE was presented as a
significant risk factor (HR Z 1.995) for overall mortality.
Thus, they concluded that preoperative TACE did not
benefit patients with resectable HCC. The results of our
study are consistent with the studies showing thatlone and TACE plus sequential curative therapy according to
n mo of OS
CE plus/
tive alone)
p Median mo of DFS
TACE plus/
curative alone)
p
.3/30.1 0.124 24.4/24.5 0.122
.3/30.6 0.075 17.8/20.4 0.211
.3/28.3 0.303 20.8/22.1 0.230
.0/30.3 0.113 23.5/24.0 0.429
.3/32.4 0.167 22.0/26.5 0.272
.5/27.6 0.310 19.8/21.9 0.644
.3/30.8 0.299 24.5/19.5 0.582
.0/30.6 0.015 22.3/23.6 0.069
.3/24.1 0.202 22.1/16.3 0.691
.3/29.6 0.002 20.3/21.8 0.004
.6/30.1 0.538 24.3/24.1 0.821
.6/29.6 0.062 23.7/22.6 0.072
.1/30.5 0.680 20.3/25.2 0.609
.6/31.1 0.254 24.3/23.1 0.503
.0/25.4 0.099 11.2/19.7 0.131
disease-free survival; HBVZ hepatitis B virus; HCVZ hepatitis
mbolization.
82 M.-L. Yeh et al.neoadjuvant TACE does not provide survival or recurrence
benefit. However, there are still some discrepancies be-
tween our study and others. Firstly, we only focused on
single HCC because of the high recurrence rate after
resection in multiple HCC with/without portal vein
thrombosis. Secondly, we tried to identify conditions that
showed differences between the TACE and non-TACE
groups. As such, we performed subgroup analysis and
found that the TACE group had significantly poor OS and
DFS, especially in patients of Child-Pugh class A and BCLC
very early stage.
Recently, a prospective randomized trial by Peng et al
[18] demonstrated that sequential TACE-RFA resulted in
significantly better overall and recurrence-free survival
than RFA alone for recurrent HCC, especially in patients
with tumors measuring 3.1e5.0 cm. Another prospective
randomized trial by the same study group [19] found that
TACE-RFA was superior to RFA alone in improving survival
for patients with HCC < 7 cm. The effect of TACE combined
with RFA in improving OS was also demonstrated in a
recently published meta-analysis [20]. However, in the
present study, we did not observe the same benefits of
TACE plus sequential RFA in improving OS and DFS.
Some limitations of the present study were noted.
Firstly, data on the presence of other comorbidities in pa-
tients, which influences the decision on treatment options,
and data regarding secondary prevention of HCC, such as
antiviral therapy, were lacking. Secondly, we could not
identify the patterns of recurrence (local, regional, or
distant recurrence) from the database. As such, whether
the patterns of recurrence differ among different treat-
ments is unknown. Thirdly, the influence of neoadjuvant
TACE on the performing of sequential curative therapy
could not be analyzed.
In conclusion, TACE prior to sequential curative therapy,
including surgery or RFA, did not provide survival or
recurrence-free benefits in single HCC. Neoadjuvant TACE
should not be recommended in single HCC patients who are
indicated for curative therapy.Acknowledgments
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